Low patient accrual rates cause termination of over 25 per cent rare disease trials: GlobalData Read more
Lilly’s bamlanivimab plus etesevimab cut death, hospitalisations for early COVID-19 in Phase III trial Read more
Pfizer interested in producing vaccine in India if speedy clearance, export freedom assured: Reports Read more